Tyra Biosciences Inc (TYRA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Tyra Biosciences Inc stock $16.11, price $19.74, that is 18.4% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Tyra Biosciences Inc
TYRA · USExpensive (fair value 18% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range $5.26 – $39.61 · fair‑value band $12.09 – $20.14 · the $19.74 price screens above the $16.11 fair value. As of Nov 14, 2026.
Every Wednesday you see whether Tyra Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
Show moreShow less
The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma.
Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Stock analysis
Tyra Biosciences Inc (TYRA) currently trades at $19.74, while our estimate is $16.11, 18% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $12.09 (bear) to $20.14 (bull), the price of $19.74 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Tyra Biosciences Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$120M in FY2025.
Key figures
Market cap $1.3B Small · EPS (TTM) $−2.63 · Return on equity −34.9% · Return on assets (EBIT) −28.3% (5-year average) · Free cash flow −$95.3M · Net cash $71.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −18%, TYRA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $20,002, on Sep 9, 2026.
- BuyRehan VerjeeDirector972 shares at $20.58$20,002Sep 9, 2026
- SaleGilla KaplanDirector14,295 shares at $36.97$528,486Mar 25, 2026
- SaleDaniel BensenChief Discovery Officer5× since Nov 17, 2025: 169,661 shares, avg. $17.85$3.0MFeb 12, 202610b5-1 plan
- SaleRobert J MoreDirector2× since Nov 21, 2025: 256,871 shares, avg. $20.43$5.2MDec 19, 202510b5-1 plan
Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Tyra Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs TYRA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs TYRA |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs TYRA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs TYRA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs TYRA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs TYRA |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs TYRA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs TYRA |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs TYRA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs TYRA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Tyra Biosciences Inc (TYRA) overvalued or undervalued?
What is the fair value of TYRA?
What is the quality score of TYRA?
What is the price target for Tyra Biosciences Inc (TYRA)?
What is the Tyra Biosciences Inc stock forecast for 2026?
What is the intrinsic value of Tyra Biosciences Inc (TYRA)?
Is Tyra Biosciences Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of TYRA?
How much is Tyra Biosciences Inc worth?
What do the bullish and bearish scenarios say about TYRA?
How solid is the balance sheet of Tyra Biosciences Inc (TYRA)?
How far is TYRA from its 52-week high?
Which stocks are comparable to Tyra Biosciences Inc?
Is Tyra Biosciences Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Tyra Biosciences Inc (TYRA)?
What should I pay attention to with Tyra Biosciences Inc right now?
Key figures of Tyra Biosciences Inc
How large is the market capitalisation of Tyra Biosciences Inc (TYRA)?
What are the earnings per share of Tyra Biosciences Inc (TYRA)?
What is the return on equity of Tyra Biosciences Inc (TYRA)?
What is the EBIT return on assets of Tyra Biosciences Inc (TYRA)?
How much free cash flow does Tyra Biosciences Inc (TYRA) generate?
How much net cash does Tyra Biosciences Inc (TYRA) hold?
Watch Tyra Biosciences Inc in the live analysis
One click puts Tyra Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.